Evidence map›Paper›PMID 36992380›Full record

Observational studyViruses2023

Serum Lactate Dehydrogenase Level One Week after Admission Is the Strongest Predictor of Prognosis of COVID-19: A Large Observational Study Using the COVID-19 Registry Japan.

Sho Nakakubo, Yoko Unoki, Koji Kitajima, Mari Terada, Hiroyuki Gatanaga, Norio Ohmagari, Isao Yokota, Satoshi Konno

Abstract readObservational Study
In one paragraph

Observational study in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sho NakakuboDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo 060-8638, Japan.ORCID 0000-0003-1560-8361
Yoko UnokiDepartment of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
Koji KitajimaCentre for Clinical Sciences, National Centre for Global Health and Medicine, Tokyo 162-8655, Japan.
Mari TeradaCentre for Clinical Sciences, National Centre for Global Health and Medicine, Tokyo 162-8655, Japan.
Hiroyuki GatanagaAIDS Clinical Centre, National Centre for Global Health and Medicine, Tokyo 162-8655, Japan.
Norio OhmagariDisease Control and Prevention Centre, National Centre for Global Health and Medicine, Tokyo 162-8655, Japan.
Isao YokotaDepartment of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
Satoshi KonnoDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo 060-8638, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical features of COVID-19 are diverse, and a useful tool for predicting clinical outcomes based on clinical characteristics of COVID-19 is needed. This study examined the laboratory values and trends that influence mortality in hospitalised COVID-19 patients. Data on hospitalised patients enrolled in a registry study in Japan (COVID-19 Registry Japan) were obtained. Patients with records on basic information, outcomes, and laboratory data on the day of admission (day 1) and day 8 were included. In-hospital mortality was set as the outcome, and associated factors were identified by multivariate analysis using the stepwise method. A total of 8860 hospitalised patients were included. The group with lactate dehydrogenase (LDH) levels >222 IU/L on day 8 had a higher mortality rate compared to the group with LDH levels ≤222 IU/L. Similar results were observed in subgroups formed by age, body mass index (BMI), underlying disease, and mutation type, except for those aged <50 years. When age, sex, BMI, underlying disease, and laboratory values on days 1 and 8 were tested for factors strongly associated with in-hospital mortality, LDH on day 8 was most strongly associated with mortality. LDH level on day 8 was the strongest predictor of in-hospital mortality in hospitalised COVID-19 patients, indicating its potential usefulness in post-treatment decision-making in severe COVID-19 cases.

Indexed as

COVID-19HumansJapanLactate DehydrogenasesPrognosisRetrospective StudiesSARS-CoV-2Lactate DehydrogenasesCOVID-19COVID-19 registry Japanlactate dehydrogenaseSARS-CoV-2

Identifiers

PMID36992380
PMCPMC10058713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.